MARKET

MRNA

MRNA

Moderna
NASDAQ
107.97
+1.79
+1.69%
After Hours: 108.01 +0.04 +0.04% 17:01 04/26 EDT
OPEN
106.18
PREV CLOSE
106.18
HIGH
108.19
LOW
105.25
VOLUME
2.24M
TURNOVER
0
52 WEEK HIGH
142.79
52 WEEK LOW
62.55
MARKET CAP
41.34B
P/E (TTM)
-8.7494
1D
5D
1M
3M
1Y
5Y
What to Watch in the Week Ahead and on Monday, April 29
Domino's Pizza expected to post a rise in first-quarter revenue on resilient demand for its pizzas. Apple's revenue is expected to decline 5% in the week. The U.S. Economic calendar has a flurry of data due in the next few days.
Reuters · 2h ago
MRNA June 2026 Options Begin Trading
NASDAQ · 3h ago
Should You Buy Moderna Before May 12?
Moderna's respiratory syncytial virus (RSV) vaccine candidate is set to be approved by the FDA by May 12. The biotech company aims to launch 15 new products over the next five years. Moderna is a terrific long-term buy. The company's RSV vaccine is the company's only commercialized product.
The Motley Fool · 12h ago
What's Going On With Pfizer Stock On Thursday?
GSK Plc has reportedly taken legal action against Pfizer Inc and BioNTech SE in a Delaware federal court. The lawsuit alleges patent infringement concerning mRNA technology used in the COVID-19 vaccines. GSK says its patents underpin the technology used to develop the vaccines. Pfizer says it will defend against GSK's claims.
Benzinga · 1d ago
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents
GSK sues Pfizer, BioNTech over COVID-19 vaccines patents. GSK is suing Pfizer and partner for patent infringement over the use of certain mRNA technology for their Comirnaty vaccines. The case is the latest filed by GSK against Pfizer over technology in its vaccines.
Seeking Alpha · 1d ago
UPDATE 3-GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology. Company accuses them of infringing GSK patents related to messenger RNA technology in the companies' blockbuster vaccines. GSK says the vaccines violate the company's patent rights in mRNA-vaccine innovations.
Reuters · 1d ago
How Is The Market Feeling About Moderna?
Moderna's short percent of float has fallen 3.53% since its last report. The company has 21.44 million shares sold short, which is 7.38% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 1d ago
Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?
Moderna Inc announced an ongoing collaboration with OpenAI. The company and Microsoft Corp.-backed OpenAI share a vision of AI’s transformative potential in the future of business and healthcare. Moderna says it has reached more than 80% internal adoption of OpenAI's ChatGPT.
Benzinga · 2d ago
More
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Its diverse development pipeline consists of 45 therapeutic and vaccine programs, nine of which are in late-stage development. Its products include COVID-19 vaccines (mRNA-1273/Spikevax, next-generation mRNA-1283), RSV vaccine (mRNA-1345), Seasonal influenza vaccines (mRNA-1010, mRNA-1011, mRNA-1012, mRNA-1020 and mRNA-1030), Combination vaccines (mRNA-1083, mRNA-1230, mRNA-1045 and mRNA-1365), CMV vaccine (mRNA-1647), EBV vaccine (mRNA-1189 and mRNA-1195) and others.

Webull offers Moderna Inc stock information, including NASDAQ: MRNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MRNA stock methods without spending real money on the virtual paper trading platform.